Last Close
Feb 03  •  04:00PM ET
184.32
Dollar change
-4.09
Percentage change
-2.17
%
Feb 03, 7:00 AMAstraZeneca reports that the FDA has accepted and granted Priority Review to its and Daiichi Sankyo’s supplemental BLA for Datroway (datopotamab deruxtecan) in unresectable or metastatic triple-negative breast cancer, with a PDUFA decision expected in the second quarter of 2026.
Index- P/E30.61 EPS (ttm)6.02 Insider Own4.81% Shs Outstand1.55B Perf Week-1.99%
Market Cap285.78B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.48B Perf Month0.90%
Enterprise Value310.32B PEG- EPS next Q- Inst Own53.77% Short Float- Perf Quarter9.53%
Income9.40B P/S4.92 EPS this Y- Inst Trans- Short Ratio- Perf Half Y28.76%
Sales58.13B P/B6.23 EPS next Y- ROA8.57% Short Interest- Perf YTD5.03%
Book/sh29.60 P/C34.93 EPS next 5Y- ROE21.70% 52W High195.00 -5.48% Perf Year40.57%
Cash/sh5.28 P/FCF21.82 EPS past 3/5Y285.86% 34.63% ROIC13.06% 52W Low122.26 50.76% Perf 3Y53.32%
Dividend Est.- EV/EBITDA16.11 Sales past 3/5Y12.64% 17.27% Gross Margin73.23% Volatility3.71% 2.77% Perf 5Y78.33%
Dividend TTM3.16 (1.71%) EV/Sales5.34 EPS Y/Y TTM44.64% Oper. Margin21.86% ATR (14)6.88 Perf 10Y317.11%
Dividend Ex-DateAug 08, 2025 Quick Ratio0.69 Sales Y/Y TTM13.52% Profit Margin16.17% RSI (14)50.23 Recom-
Dividend Gr. 3/5Y2.80% 2.47% Current Ratio0.88 EPS Q/Q77.36% SMA20-0.86% Beta0.39 Target Price-
Payout69.15% Debt/Eq0.71 Sales Q/Q11.99% SMA500.64% Rel Volume45.56 Prev Close188.41
Employees94300 LT Debt/Eq0.57 EarningsFeb 10 BMO SMA20016.46% Avg Volume105.01K Price184.32
IPOOct 17, 2003 Option/ShortYes / Yes EPS/Sales Surpr.3.80% 2.79% Trades Volume2,659,379 Change-2.17%
Feb-03-26 06:15PM
02:30PM
11:48AM
11:36AM
11:34AM
11:02AM Loading…
11:02AM
07:00AM
06:55AM
05:11AM
04:34AM
02:42AM
Feb-02-26 02:15PM
02:04PM
12:29PM
11:00AM
10:01AM Loading…
10:01AM
07:00AM
Jan-30-26 12:28PM
11:11AM
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company's history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.